reports
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Co...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Conference Call on May 8th DENVER, April 16, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, May 7, 2024, Angi Inc. (NASDAQ: ANGI) will post its first quarter results at . On Wednesday May 8, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective first quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi Inc. Angi (NASDAQ: ANGI) helps...
Greif Inc: 1 director
A director at Greif Inc bought 10,082 shares at 68.234USD and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Angi Appoints Jeff Kip as CEO
Angi Appoints Jeff Kip as CEO DENVER, April 08, 2024 (GLOBE NEWSWIRE) -- Angi (NASDAQ: ANGI), the leading and most comprehensive solution for all home care needs, today announced the appointment of Angi President and long-time IAC and Angi executive Jeff Kip to CEO, succeeding Joey Levin. As CEO, Mr. Kip will lead Angi’s executive team, overseeing strategy and daily management of the company. Mr. Levin, CEO of IAC, will continue as Chairman of the Angi Board of Directors. All changes are effective immediately. “Through multiple roles, Jeff Kip has been a student of the Angi business, fir...
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosi...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA. “We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP,” said M...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 125,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara...
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Prov...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update. “We look forward to reporting IMPALA-2 top line results at the end of the second quarter and, assuming positive data, anticipate filing the BLA in the first half of 2025,” said Matt Pauls, Chair and CEO, Savara. “2023 was a year of strong execution that included the on-time, over-enrollment of the Phase 3 IMPALA-2 trial and an an...
Savara to Present at the Barclays 26th Annual Global Healthcare Confer...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocy...
Angi Inc. Earnings Release Available on Company’s Website
Angi Inc. Earnings Release Available on Company’s Website DENVER, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its fourth quarter financial results on the investor relations section of its website at . As announced previously, Angi Inc. and IAC will host a conference call to discuss both companies’ respective fourth quarter results and to answer questions. The call will be held on Wednesday, February 14, 2024, at 8:30 a.m. ET. Joey Levin, CEO of IAC and CEO and Chairman of Angi Inc., and Christopher Halpin, Executive Vice President, CFO and COO of IAC, will participat...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 70,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 30,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2...
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Corporate Presentation Virtual Conference A webcast of each presentation will be available through the Inve...
Angi Inc. to Announce Q4 2023 Earnings on February 13th and Host Earni...
Angi Inc. to Announce Q4 2023 Earnings on February 13th and Host Earnings Conference Call on February 14th DENVER, Jan. 17, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, February 13, 2024, Angi Inc. (NASDAQ: ANGI) will post its fourth quarter results at . On Wednesday February 14, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective fourth quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi In...
Savara Inc: 3 directors
Three Directors at Savara Inc sold after exercising options/gave away/sold 206,843 shares at between 0.000USD and 4.713USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF. Autoimmune PAP accounts for approximately 90% of all patients with PAP and has an estimated diagnosed prevalence of seven cases per million in the U.S. and similar or higher prevalence reported elsewhere in the world. The aPAP ...
Savara Added to the NASDAQ Biotechnology Index
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified ca...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 110,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 80,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc....
U.S. Homeowners Double Down on Home Improvement Spending in 2023
U.S. Homeowners Double Down on Home Improvement Spending in 2023 Angi’s annual “” report shows increased spending on home improvement projects in 2023 Overall spend on home improvement grew 6% to $13,667 and an average of 11.1 projects per household in 2023Rising mortgage rates was a driver of home improvement spending: 40% of homeowners say they spent more on home projects as opposed to moving due to high interest rates DENVER, Dec. 07, 2023 (GLOBE NEWSWIRE) -- , a leading and comprehensive solution for improving and maintaining homes, today released its which found that homeowners, de...
Angi Announces 2023 Super Service Award Winners
Angi Announces 2023 Super Service Award Winners Angi Recognizes Home Pros Who Represent the Highest Quality, Service and Value, and Get Jobs Done Well with the 24th Annual Super Service Award. DENVER, Nov. 30, 2023 (GLOBE NEWSWIRE) -- , a leading and comprehensive solution for improving and maintaining homes, announced the winners of the 2023 Angi Super Service Award. This award, first released in 1999, recognizes the best home professionals and businesses in the Angi network for their hard work, dedication, and commitment to providing Angi customers a great experience. “Angi is commit...
Savara to Present at the Piper Sandler 35th Annual Healthcare Conferen...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granul...
Savara Reports Third Quarter Financial Results and Provides Business U...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update. “We remain on track to report top line data from the pivotal, Phase 3 IMPALA-2 trial by the end of the second quarter 2024,” said Matt Pauls, Chair and CEO, Savara. “In parallel, we are working to provide pulmonologists in the U.S. and Europe with a simple, accurate, no-cost, laboratory-based antibody blood test for aPAP. This antibody test is...
Savara to Present at the Jefferies London Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.